LENZ LENZ Therapeutics, Inc.
$3.46-1.14%
Last close: · regular session · Last 60 sessions
After-hours $3.41 -1.45% ·
- Float
- 19.5M
- Last filing
- 4 · Nov 4, 2026
Latest SEC filings for LENZ
| 4 | Insider transaction | |
| SCHEDULE 13G | ||
| 10-Q | Quarterly report | |
| 4 | Insider transaction | |
| SCHEDULE 13D/A | ||
| 8-K | Current report | |
| SCHEDULE 13G/A | ||
| SCHEDULE 13G/A | ||
| 8-K | Current report | |
| 10-Q | Quarterly report |
Dilution today: new offering filings and reverse splits
Float: 19.5M shares. Latest SEC filing: 4 on Nov 4, 2026. LENZ closed at $3.46 (-1.14%) on Nov 4, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for LENZ in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 6
- Website: https://www.lenz-tx.com
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Latest LENZ news
- LENZ Therapeutics GAAP EPS of -$0.99 misses by $0.04, revenue of $3.38M misses by $0.82M Read article
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ Read article
Recent dilution filers
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.